Study protocol of Elective Para-aortic and pelvic versus Pelvic only Irradiation in pelvic node positive Cervical cancer: a multicentric open labelled phase III randomised controlled trial (EPIC Study).

Autor: Shinghal A; Radiation Oncology, Mahamana Pandit Madan Mohan Malaviya Cancer Centre, Varanasi, Uttar Pradesh, India abhishek.shinghal@gmail.com.; Radiation Oncology, Homi Bhabha Cancer Hospital, Varanasi, Uttar Pradesh, India.; Homi Bhabha National Institute, Mumbai, Maharashtra, India., Pradhan S; Radiation Oncology, Mahamana Pandit Madan Mohan Malaviya Cancer Centre, Varanasi, Uttar Pradesh, India.; Radiation Oncology, Homi Bhabha Cancer Hospital, Varanasi, Uttar Pradesh, India.; Homi Bhabha National Institute, Mumbai, Maharashtra, India., Chopra S; Homi Bhabha National Institute, Mumbai, Maharashtra, India.; Radiation Oncology, ACTREC, Navi Mumbai, Maharashtra, India., Kapoor AR; Radiation Oncology, Mahamana Pandit Madan Mohan Malaviya Cancer Centre, Varanasi, Uttar Pradesh, India.; Radiation Oncology, Homi Bhabha Cancer Hospital, Varanasi, Uttar Pradesh, India.; Homi Bhabha National Institute, Mumbai, Maharashtra, India., Gupta A; Homi Bhabha National Institute, Mumbai, Maharashtra, India.; Radiation Oncology, ACTREC, Navi Mumbai, Maharashtra, India., Mittal P; Homi Bhabha National Institute, Mumbai, Maharashtra, India.; Radiation Oncology, Tata Memorial Centre, Mumbai, Maharashtra, India., Saini V; Radiation Oncology, Mahamana Pandit Madan Mohan Malaviya Cancer Centre, Varanasi, Uttar Pradesh, India.; Radiation Oncology, Homi Bhabha Cancer Hospital, Varanasi, Uttar Pradesh, India.; Homi Bhabha National Institute, Mumbai, Maharashtra, India., Jain J; Homi Bhabha National Institute, Mumbai, Maharashtra, India.; Radiation Oncology, ACTREC, Navi Mumbai, Maharashtra, India., Sanju S; Radiation Oncology, Mahamana Pandit Madan Mohan Malaviya Cancer Centre, Varanasi, Uttar Pradesh, India.; Radiation Oncology, Homi Bhabha Cancer Hospital, Varanasi, Uttar Pradesh, India.; Homi Bhabha National Institute, Mumbai, Maharashtra, India., Kapoor A; Homi Bhabha National Institute, Mumbai, Maharashtra, India.; Medical Oncology, Mahamana Pandit Madan Mohan Malaviya Cancer Centre, Varanasi, Uttar Pradesh, India.; Medical Oncology, Homi Bhabha Cancer Hospital, Varanasi, Uttar Pradesh, India., Giridhar P; Radiation Oncology, Mahamana Pandit Madan Mohan Malaviya Cancer Centre, Varanasi, Uttar Pradesh, India.; Radiation Oncology, Homi Bhabha Cancer Hospital, Varanasi, Uttar Pradesh, India.; Homi Bhabha National Institute, Mumbai, Maharashtra, India., Pujari L; Radiation Oncology, Mahamana Pandit Madan Mohan Malaviya Cancer Centre, Varanasi, Uttar Pradesh, India.; Radiation Oncology, Homi Bhabha Cancer Hospital, Varanasi, Uttar Pradesh, India.; Homi Bhabha National Institute, Mumbai, Maharashtra, India., Chowdhury Z; Homi Bhabha National Institute, Mumbai, Maharashtra, India.; Oncopathology, Mahamana Pandit Madan Mohan Malaviya Cancer Centre, Varanasi, Uttar Pradesh, India.; Oncopathology, Homi Bhabha Cancer Hospital, Varanasi, Uttar Pradesh, India., Gupta S; Homi Bhabha National Institute, Mumbai, Maharashtra, India.; Medical Oncology, Tata Memorial Centre, Mumbai, Maharashtra, India.

Publikováno v: BMJ open [BMJ Open] 2024 Nov 24; Vol. 14 (11), pp. e088223. Date of Electronic Publication: 2024 Nov 24.

Combination of a MIP3α-antigen fusion therapeutic DNA vaccine with treatments of IFNα and 5-Aza-2'Deoxycytidine enhances activated effector CD8+ T cells expressing CD11c in the B16F10 melanoma model.

Autor: Fessler K; Johns Hopkins Bloomberg School of Public Health., Zhang J; Johns Hopkins Bloomberg School of Public Health., Sandhu AK; Johns Hopkins Bloomberg School of Public Health., Hui Y; Johns Hopkins Bloomberg School of Public Health., Kapoor AR; The Johns Hopkins Hospital., Ayeh SK; The Johns Hopkins Hospital., Karanika S; The Johns Hopkins Hospital., Karakousis PC; The Johns Hopkins Hospital., Markham RB; Johns Hopkins Bloomberg School of Public Health., Gordy JT; Johns Hopkins Bloomberg School of Public Health.

Publikováno v: Research square [Res Sq] 2024 Aug 20. Date of Electronic Publication: 2024 Aug 20.

IFNα and 5-Aza-2'-deoxycytidine combined with a dendritic-cell targeting DNA vaccine alter tumor immune cell infiltration in the B16F10 melanoma model.

Autor: Gordy JT; Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States., Sandhu AK; Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States., Fessler K; Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States., Luo K; Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States., Kapoor AR; Division of Infectious Diseases, Center for Tuberculosis Research, Department of Medicine, The Johns Hopkins Hospital, Baltimore, MD, United States., Ayeh SK; Division of Infectious Diseases, Center for Tuberculosis Research, Department of Medicine, The Johns Hopkins Hospital, Baltimore, MD, United States., Hui Y; Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States., Schill C; Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States., Chen F; Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States., Wang T; Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States., Karanika S; Division of Infectious Diseases, Center for Tuberculosis Research, Department of Medicine, The Johns Hopkins Hospital, Baltimore, MD, United States., Sunshine JC; The Departments of Dermatology, Pathology, and Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, United States., Karakousis PC; Division of Infectious Diseases, Center for Tuberculosis Research, Department of Medicine, The Johns Hopkins Hospital, Baltimore, MD, United States., Markham RB; Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.

Publikováno v: Frontiers in immunology [Front Immunol] 2023 Jan 19; Vol. 13, pp. 1074644. Date of Electronic Publication: 2023 Jan 19 (Print Publication: 2022).

An intranasal stringent response vaccine targeting dendritic cells as a novel adjunctive therapy against tuberculosis.

Autor: Karanika S; Division of Infectious Diseases, Department of Medicine, The Johns Hopkins Hospital, Baltimore, MD, United States.; W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States., Gordy JT; Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States., Neupane P; Division of Infectious Diseases, Department of Medicine, The Johns Hopkins Hospital, Baltimore, MD, United States.; W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States., Karantanos T; Division of Hematological Malignancies, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University Hospital, Baltimore, MD, United States., Ruelas Castillo J; Division of Infectious Diseases, Department of Medicine, The Johns Hopkins Hospital, Baltimore, MD, United States.; W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States., Quijada D; Division of Infectious Diseases, Department of Medicine, The Johns Hopkins Hospital, Baltimore, MD, United States.; W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States., Comstock K; Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States., Sandhu AK; Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States., Kapoor AR; Division of Infectious Diseases, Department of Medicine, The Johns Hopkins Hospital, Baltimore, MD, United States.; Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States., Hui Y; Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States., Ayeh SK; Division of Infectious Diseases, Department of Medicine, The Johns Hopkins Hospital, Baltimore, MD, United States.; W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States., Tasneen R; Division of Infectious Diseases, Department of Medicine, The Johns Hopkins Hospital, Baltimore, MD, United States.; W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States., Krug S; Division of Infectious Diseases, Department of Medicine, The Johns Hopkins Hospital, Baltimore, MD, United States.; W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States., Danchik C; Division of Infectious Diseases, Department of Medicine, The Johns Hopkins Hospital, Baltimore, MD, United States.; W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States., Wang T; Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States., Schill C; Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States., Markham RB; Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States., Karakousis PC; Division of Infectious Diseases, Department of Medicine, The Johns Hopkins Hospital, Baltimore, MD, United States.; W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.

Publikováno v: Frontiers in immunology [Front Immunol] 2022 Sep 16; Vol. 13, pp. 972266. Date of Electronic Publication: 2022 Sep 16 (Print Publication: 2022).